Vol.56 No.6 November 2008
Cost benefit of triple CZOP administration for febrile neutropenia
1)Department of Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, 465 Kajii-cho, Kamigyo-ku, Kyoto, Japan
2)Department of Microbiology, Kyoto Prefectural Institute of Public Health and Environment
3)Department of Molecular Laboratory Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science
Abstract
Fourth-generation cephems used as a first-line agent for febrile neutropenia, in Japan, are usually administrated twice a day. Administration three times a day has, however, proven to be more efficacious, although its cost benefit remains unknown. We conducted a prospective clinical trial using cefozopran (2 g, 1 g, and 1 g, q8h) for febrile neutropenia from April to December 2006. Using clinical data from this trial, we determined the effective cost for one dose to be 63,036 yen. Administration twice a day (2 g, 2 g, and q12h) cost 78,327 yen. In conclusion, we found that administration three times is more effective than twice a day in cost and effectiveness. The cost antifungal agents must thus be studied more carefully.
Key word
cefozopran, febrile neutropenia, cost-effectiveness, optimal dosage
Received
May 15, 2008
Accepted
July 4, 2008
Jpn. J. Chemother. 56 (6): 631-633, 2008
